Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market

An EU filing by licensee Bayer puts Loxo Oncology’s larotrectinib on track to be the first tropomysosin receptor kinase inhibitor to reach the market there. Meanwhile, Loxo’s second product, LOXO-292, is speeding its way to a US filing.